Avalo Therapeutics (AVTX) announced that it has entered into a milestone buyout option and amendment agreement related to the company’s prior acquisition of AlmataBio in March of 2024. Pursuant to the buyout agreement, Avalo has agreed to pay $2.25M to the former AlmataBio securityholders for an option, exercisable within 90 days of the effective date, to pay an additional $5.13M in cash or shares of Avalo common stock, or a combination thereof in lieu of a previously disclosed $15M contingent milestone payment due upon the first patient being dosed in a Phase 3 trial.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics Restructures AlmataBio Milestone Payment Obligations
- Avalo Therapeutics initiated with an Outperform at Wolfe Research
- Avalo Therapeutics initiated with an Outperform at Citizens
- Avalo Therapeutics price target raised to $40 from $25 at H.C. Wainwright
- AVTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?